Osteomyelitis - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463993 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License


Osteomyelitis - Pipeline Review, H2 2019


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteomyelitis - Pipeline Review, H2 2019, provides an overview of the Osteomyelitis (Infectious Disease) pipeline landscape.

Osteomyelitis is an infection in a bone. Infections can reach a bone by traveling through the bloodstream or spreading from nearby tissue. Symptoms include fever, pain in the area of the infection, swelling, warmth and redness over the area of the infection and irritability. Risk factors bone fracture, sickle cell disease, chemotherapy, diabetes and peripheral arterial disease. Treatment includes surgery and oral antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteomyelitis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Osteomyelitis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteomyelitis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Osteomyelitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 2 and 3 respectively.

Osteomyelitis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteomyelitis (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Osteomyelitis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Osteomyelitis (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Osteomyelitis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Osteomyelitis (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Osteomyelitis (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Osteomyelitis (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage

Osteomyelitis - Overview

Osteomyelitis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Osteomyelitis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteomyelitis - Companies Involved in Therapeutics Development

Allergan Plc

Debiopharm International SA

Motif Bio Plc

Telephus Medical LLC

Osteomyelitis - Drug Profiles

afabicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ceforanide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalbavancin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MTF-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TPH-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Osteomyelitis - Dormant Projects

Osteomyelitis - Product Development Milestones

Featured News & Press Releases

Apr 12, 2018: Cardiome Announces Xydalba Abstracts at ECCMID 2018

Dec 11, 2017: Telephus Biosciences Appoints Patrick Vink, M.D., MBA, William Boyle, Ph.D., and Richard Proctor, M.D., as Company Advisors

Oct 24, 2016: Allergan to Present New Data on DALVANCE (dalbavancin) at IDWeek 2016 in New Orleans

Apr 08, 2016: Debiopharm International to present the latest findings on Debio 1450 at ECCMID

Oct 10, 2014: Durata Therapeutics Presents New Data for DALVANCE(TM) at IDWeek 2014




Secondary Research

Primary Research

Expert Panel Validation

Contact Us


Additional Details


Global Markets Direct

Publisher Information


1463993 | GMDHC11441IDB

Number of Pages


Report Format


Related Reports

Date Published
Price From

Published by Global Markets Direct

$2,000 USD

Published by Global Markets Direct

$2,000 USD

Published by Global Data

$2,500 USD

Published by Global Markets Direct

$2,000 USD

Published by Global Markets Direct

$2,000 USD

Published by Global Markets Direct

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Osteomyelitis - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types


Buy now using our secure payment system.